Latest News Sunday, Jun 5, 2016 Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Business Wire - 10 minutes ago J&J myeloma drug, in combo regimen, delays worsening of the disease Reuters - 15 minutes ago Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting Business Wire - 15 minutes ago Stemline Therapeutics SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds GlobeNewswire - Sat 7:07 pm ET TESARO Provides Pipeline Update at ASCO Investor Briefing GlobeNewswire - Sat 7:00 pm ET Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer Business Wire - Sat 5:32 pm ET Juno Therapeutics Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL Business Wire - Sat 5:15 pm ET Saturday, Jun 4, 2016 Celldex Therapeutics CDX1401, CDX301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma GlobeNewswire - Sat 2:02 pm ET Juno Therapeutics Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability Business Wire - Sat 10:08 am ET Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting GlobeNewswire - Sat 9:24 am ET Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks PR Newswire - Sat 9:00 am ET Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial PR Newswire - Sat 9:00 am ET Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO GlobeNewswire - Sat 9:00 am ET Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 PR Newswire - Sat 9:00 am ET ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations Business Wire - Sat 7:35 am ET ARIAD Presents Long-Term Phase 1\/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients Business Wire - Sat 7:35 am ET INTREXON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Intrexon Corporation Business Wire - Fri 10:07 pm ET June is month to watch for more IPO news at bizjournals.com - Fri 8:47 pm ET [$$] Frazier, OrbiMed Join $100M Financing for Lion Biotechnologies at The Wall Street Journal Online - Fri 8:44 pm ET Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders PR Newswire - Fri 6:21 pm ET More Latest News...<\/p>\n
<\/p>\n
Read more here: Latest News Sunday, Jun 5, 2016 Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Business Wire - 10 minutes ago J&J myeloma drug, in combo regimen, delays worsening of the disease Reuters - 15 minutes ago Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting Business Wire - 15 minutes ago Stemline Therapeutics SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds GlobeNewswire - Sat 7:07 pm ET TESARO Provides Pipeline Update at ASCO Investor Briefing GlobeNewswire - Sat 7:00 pm ET Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer Business Wire - Sat 5:32 pm ET Juno Therapeutics Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL Business Wire - Sat 5:15 pm ET Saturday, Jun 4, 2016 Celldex Therapeutics CDX1401, CDX301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma GlobeNewswire - Sat 2:02 pm ET Juno Therapeutics Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability Business Wire - Sat 10:08 am ET Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting GlobeNewswire - Sat 9:24 am ET Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks PR Newswire - Sat 9:00 am ET Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial PR Newswire - Sat 9:00 am ET Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO GlobeNewswire - Sat 9:00 am ET Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 PR Newswire - Sat 9:00 am ET ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations Business Wire - Sat 7:35 am ET ARIAD Presents Long-Term Phase 1\/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients Business Wire - Sat 7:35 am ET INTREXON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Intrexon Corporation Business Wire - Fri 10:07 pm ET June is month to watch for more IPO news at bizjournals.com - Fri 8:47 pm ET [$$] Frazier, OrbiMed Join $100M Financing for Lion Biotechnologies at The Wall Street Journal Online - Fri 8:44 pm ET Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders PR Newswire - Fri 6:21 pm ET More Latest News... Continue reading
\nBiotechnology Industry News: Industry Center - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"